María T Ríos

TL;DR: Routine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control and, most importantly, markedly diminished occurrence of major CVD events.

TL;DR: Asleep systolic blood pressure (SBP) mean was the most significant BP-derived risk factor for the primary outcome and treatment-induced decrease of asleep, but not awake SBP, a novel hypertension therapeutic target requiring periodic patient evaluation by ambulatory monitoring, is associated with significantly lower risk for CVD morbidity and mortality.

TL;DR: A progressive reduction in blood pressure during sleep is identified—a novel therapeutic target best achieved by ingestion of one or more hypertension medications at bedtime—as the most significant predictor of decreased cardiovascular risk in patients with and without CKD.

TL;DR: The collective findings indicate that bedtime hypertension treatment, in conjunction with proper patient evaluation by ABPM to corroborate the diagnosis of hypertension and avoid treatment-induced nocturnal hypotension, should be the preferred therapeutic scheme for CKD.

TL;DR: A significantly elevated prevalence of a blunted nighttime BP decline in patients here categorized as either false isolated-office RH and true RH is document, which indicates that classification of RH patients into categories of isolated- office RH, masked RH, and trueRH cannot be based on either daytime home BP measurements or awake BP mean.